143 related articles for article (PubMed ID: 1467385)
1. Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients.
Kirkpatrick B; Carpenter WT; Maeda K; Buchanan RW; Breier A; Tamminga CA
Biol Psychiatry; 1992 Dec; 32(11):1049-54. PubMed ID: 1467385
[TBL] [Abstract][Full Text] [Related]
2. Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation.
Kirkpatrick B; Buchanan RW; Maeda K; Carpenter WT; Jauch D; Tamminga CA
Biol Psychiatry; 1989 Jun; 26(2):131-8. PubMed ID: 2567610
[TBL] [Abstract][Full Text] [Related]
3. Pupillary constriction during haloperidol treatment as a predictor of relapse following drug withdrawal in schizophrenic patients.
Steinhauer SR; van Kammen DP; Colbert K; Peters JL; Zubin J
Psychiatry Res; 1992 Sep; 43(3):287-98. PubMed ID: 1438625
[TBL] [Abstract][Full Text] [Related]
4. Neuroleptic responsivity of negative and positive symptoms in schizophrenia.
Breier A; Wolkowitz OM; Doran AR; Roy A; Boronow J; Hommer DW; Pickar D
Am J Psychiatry; 1987 Dec; 144(12):1549-55. PubMed ID: 3688278
[TBL] [Abstract][Full Text] [Related]
5. Prolactin bioassay in schizophrenia before and after neuroleptics.
Peabody CA; Warner MD; Griffin M; Boutros NN; Worsley IG; Friesen HG
Psychiatry Res; 1992 Mar; 41(3):249-55. PubMed ID: 1594711
[TBL] [Abstract][Full Text] [Related]
6. Phenothiazine-induced decompensation.
Van Putten T; Mutalipassi LR; Malkin MD
Arch Gen Psychiatry; 1974 Jan; 30(1):102-5. PubMed ID: 4587065
[No Abstract] [Full Text] [Related]
7. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
Faraone SV; Brown WA; Laughren TP
J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
[TBL] [Abstract][Full Text] [Related]
8. Clinical predictors of relapse following neuroleptic withdrawal.
Buchanan RW; Kirkpatrick B; Summerfelt A; Hanlon TE; Levine J; Carpenter WT
Biol Psychiatry; 1992 Jul; 32(1):72-8. PubMed ID: 1356490
[TBL] [Abstract][Full Text] [Related]
9. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.
Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
Psychiatry Res; 1992 Mar; 41(3):191-202. PubMed ID: 1594706
[TBL] [Abstract][Full Text] [Related]
10. Serum prolactin as a correlate of clinical response to haloperidol.
Van Putten T; Marder SR; Mintz J
J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
[TBL] [Abstract][Full Text] [Related]
11. Further studies with fluphenazine enanthate: II. Relapse rate in patients deprived of medication.
Ravaris CL; Weaver LA; Brooks GW
Am J Psychiatry; 1967 Aug; 124(2):248-9. PubMed ID: 4952779
[No Abstract] [Full Text] [Related]
12. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
13. A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency.
Wistedt B; Jørgensen A; Wiles D
Psychopharmacology (Berl); 1982; 78(4):301-4. PubMed ID: 6818587
[TBL] [Abstract][Full Text] [Related]
14. Life events and schizophrenic relapse after withdrawal of medication.
Ventura J; Nuechterlein KH; Hardesty JP; Gitlin M
Br J Psychiatry; 1992 Nov; 161():615-20. PubMed ID: 1422609
[TBL] [Abstract][Full Text] [Related]
15. NMS complicated by diazepam.
Velamoor VR
Br J Psychiatry; 1992 Jan; 160():135-6. PubMed ID: 1544009
[No Abstract] [Full Text] [Related]
16. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C
Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566
[TBL] [Abstract][Full Text] [Related]
17. [Prolactinemia and predictability of therapeutic response of schizophrenic patients in acute decompensation].
Vanelle JM; Amorim P; Piketti ML; Bourdel MC; Poirier-Littré MF
Encephale; 1996 Oct; 22 Spec No 3():82-4. PubMed ID: 8954284
[No Abstract] [Full Text] [Related]
18. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia.
Owen RR; Gutierrez-Esteinou R; Hsiao J; Hadd K; Benkelfat C; Lawlor BA; Murphy DL; Pickar D
Arch Gen Psychiatry; 1993 Aug; 50(8):636-44. PubMed ID: 8343034
[TBL] [Abstract][Full Text] [Related]
19. Clinical correlates of body weight changes in schizophrenia.
Lawson WB; Karson CN
J Neuropsychiatry Clin Neurosci; 1994; 6(2):187-8. PubMed ID: 8044044
[TBL] [Abstract][Full Text] [Related]
20. Dopamine antagonism by thioridazine in schizophrenia.
Meltzer HY; Sachar EJ; Frantz AG
Biol Psychiatry; 1975 Feb; 10(1):53-7. PubMed ID: 1120175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
